redox nanoparticles

Redox nanoparticles (RNPs) are self-assembling, core-shell polymeric micelle nanoparticles developed by researchers at the University of Tsukuba and licensed to its spinout company, CrestecBio. These nanoparticles are typically prepared from amphiphilic block copolymers, such as poly(ethylene glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-1-oxyl)aminomethylstyrene] (MeO-PEG-b-PMNT) or poly(ethylene glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-1-oxyl)oxymethylstyrene] (PEG-b-PMOT). In aqueous environments, these copolymers spontaneously self-assemble into micelles (approximately 20–40 nm in diameter) with a hydrophilic poly(ethylene glycol) (PEG) shell and a hydrophobic core containing nitroxide radicals (such as TEMPO or TEMPOL). RNPs act as catalytic scavengers of reactive oxygen species (ROS), protecting tissues from oxidative stress and inflammation without entering healthy cells or disrupting normal intracellular redox reactions. The lead clinical candidate, CTB211, is being developed for the treatment of acute ischemic stroke to suppress reperfusion injury following thrombectomy, and is preparing for Phase Ib/IIa clinical trials. Other formulations and applications are under preclinical investigation for hepatic ischemia-reperfusion injury, colitis, nonalcoholic steatohepatitis, malaria, Parkinson's disease, and triple-negative breast cancer.

Other names

MeO-PEG-b-PMNTNanoAOXnitroxide radical-containing nanoparticlesPEG-b-PMNTPEG-b-PMOTredox polymer nanotherapeuticsRNPRNPNRNPO